A5076876391- Microtubule and mitosis dynamics
- Pancreatic function and diabetes
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
- Genetics and Neurodevelopmental Disorders
- Ubiquitin and proteasome pathways
- Hippo pathway signaling and YAP/TAZ
- Pancreatic and Hepatic Oncology Research
- Pluripotent Stem Cells Research
- Acute Myeloid Leukemia Research
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Cancer Mechanisms and Therapy
- PI3K/AKT/mTOR signaling in cancer
Universidad Autónoma de Madrid
2021-2025
Instituto de Investigaciones Biomédicas Sols-Morreale
2021-2025
Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant 'stem-like' cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus, comprehending how this subset of evades the system is crucial for advancing novel therapies.
New therapeutic targets are revolutionizing colorectal cancer clinical management, opening new horizons in metastatic patients' outcome. Polo Like Kinase1 (PLK1) inhibitors have high potential as antitumoral agents, however, the emergence of drug resistance is a major challenge for their use practice. Overcoming this represents hot topic current discovery research. BI2536-resistant cell lines HT29R, RKOR, SW837R and HCT116R, were generated vitro validated by IG50 assays xenografts models T/C...
Chromosomal instability (CIN) is a hallmark of cancer aggressiveness, providing genetic plasticity and tumor heterogeneity that allows the to evolve adapt stress conditions. CIN considered therapeutic biomarker because healthy cells do not exhibit CIN. Despite recent efforts identify strategies related CIN, results obtained have been very limited. characterized by signature where collection genes, mostly mitotic regulators, are overexpressed in CIN‐positive tumors, aggressiveness poor...
ABSTRACT Ion homeostasis is critical for numerous cellular processes, and disturbances in ionic balance underlie diverse pathological conditions, including cancer progression. Targeting ion even considered as a strategy to treat cancer. However, very little known about how may influence anticancer drug response. In genome-wide CRISPR-Cas9 resistance screen, we identified validated the master osmostress regulator WNK1 kinase modulator of response mitotic rigosertib. Osmotic stress...
Abstract Chromosomal instability (CIN) is a hallmark of cancer aggressiveness, providing genetic plasticity and tumor heterogeneity that allows the to evolve adapt stress conditions. CIN considered therapeutic biomarker because healthy cells do not exhibit CIN. Despite recent efforts identify strategies related CIN, results obtained have been very limited. characterized by signature where collection genes, mostly mitotic regulators, are overexpressed in CIN-positive tumors, aggressiveness...